BioMarin Pharmaceutical Inc.
BMRN
$58.14
$0.290.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 154.99% | 154.62% | 119.21% | 156.61% | 186.89% |
| Total Depreciation and Amortization | -13.45% | -7.63% | -2.35% | 5.10% | 4.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 47.28% | 18.85% | 57.07% | 21.37% | 28.86% |
| Change in Net Operating Assets | 10.57% | 35.70% | 8.79% | -14.20% | -27.76% |
| Cash from Operations | 149.95% | 259.69% | 199.29% | 103.96% | 90.07% |
| Capital Expenditure | 22.63% | 11.65% | 8.36% | 11.66% | 15.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6,816.65% | 1,624.87% | 3,539.62% | 95.99% | 113.53% |
| Cash from Investing | 228.30% | 222.70% | 95.17% | 56.08% | 30.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -48,911.14% | -- | -50,925.26% | 151.86% | 133.21% |
| Issuance of Common Stock | -24.02% | -28.95% | -29.74% | -38.05% | -32.68% |
| Repurchase of Common Stock | 11.30% | -1.63% | -0.77% | 3.31% | -2.87% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -36.47% | 72.63% | 85.43% | 88.07% | 94.26% |
| Cash from Financing | -2,414.36% | -2,711.17% | -2,672.84% | -94.13% | 39.09% |
| Foreign Exchange rate Adjustments | -50.53% | 269.27% | -126.28% | 54.19% | 461.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.81% | 513.53% | -560.13% | 272.45% | 758.05% |